MA51015A - Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci - Google Patents
Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ciInfo
- Publication number
- MA51015A MA51015A MA051015A MA51015A MA51015A MA 51015 A MA51015 A MA 51015A MA 051015 A MA051015 A MA 051015A MA 51015 A MA51015 A MA 51015A MA 51015 A MA51015 A MA 51015A
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- prevention
- treatment
- heart failure
- adrenergic receptor
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595133P | 2017-12-06 | 2017-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51015A true MA51015A (fr) | 2021-04-21 |
Family
ID=64744985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051015A MA51015A (fr) | 2017-12-06 | 2018-12-06 | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11339172B2 (enExample) |
| EP (1) | EP3720858B1 (enExample) |
| JP (1) | JP7357617B2 (enExample) |
| CN (1) | CN111699189B (enExample) |
| AR (1) | AR114156A1 (enExample) |
| ES (1) | ES2953576T3 (enExample) |
| MA (1) | MA51015A (enExample) |
| TW (1) | TWI822713B (enExample) |
| WO (1) | WO2019113359A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| TWI822713B (zh) * | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| EP4031132A4 (en) | 2019-09-19 | 2023-09-13 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023017388A1 (en) * | 2021-08-09 | 2023-02-16 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure |
| WO2023026185A1 (en) * | 2021-08-26 | 2023-03-02 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome |
| US20240409548A1 (en) | 2021-10-06 | 2024-12-12 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| FR2755439B1 (fr) | 1996-11-05 | 1998-12-24 | Virbac Sa | Derives aryloxypropanolamines, leur procede de preparation et leurs applications |
| DE60033964T2 (de) | 1999-12-17 | 2007-11-29 | Sanofi-Aventis | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung |
| AP2001002307A0 (en) * | 2000-10-20 | 2001-12-31 | Pfizer Prod Inc | B3 adrenergic receptor agonists and uses thereof. |
| US20080255134A1 (en) | 2004-11-30 | 2008-10-16 | Artesian Therapeutics, Inc. | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase |
| CN106999465B (zh) | 2014-10-14 | 2020-08-14 | 斯科勒普特有限公司 | 身体塑形 |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| TWI822713B (zh) * | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
-
2018
- 2018-12-06 TW TW107143855A patent/TWI822713B/zh active
- 2018-12-06 JP JP2020530969A patent/JP7357617B2/ja active Active
- 2018-12-06 WO PCT/US2018/064316 patent/WO2019113359A1/en not_active Ceased
- 2018-12-06 MA MA051015A patent/MA51015A/fr unknown
- 2018-12-06 US US16/769,507 patent/US11339172B2/en active Active
- 2018-12-06 ES ES18822236T patent/ES2953576T3/es active Active
- 2018-12-06 EP EP18822236.8A patent/EP3720858B1/en active Active
- 2018-12-06 CN CN201880088219.8A patent/CN111699189B/zh active Active
- 2018-12-06 AR ARP180103577A patent/AR114156A1/es unknown
-
2022
- 2022-04-22 US US17/726,807 patent/US11987588B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220396579A1 (en) | 2022-12-15 |
| TWI822713B (zh) | 2023-11-21 |
| EP3720858A1 (en) | 2020-10-14 |
| US11339172B2 (en) | 2022-05-24 |
| CN111699189B (zh) | 2025-02-18 |
| TW201925206A (zh) | 2019-07-01 |
| WO2019113359A1 (en) | 2019-06-13 |
| EP3720858C0 (en) | 2023-06-07 |
| CN111699189A (zh) | 2020-09-22 |
| US20200385395A1 (en) | 2020-12-10 |
| ES2953576T3 (es) | 2023-11-14 |
| JP2021505598A (ja) | 2021-02-18 |
| US11987588B2 (en) | 2024-05-21 |
| JP7357617B2 (ja) | 2023-10-06 |
| AR114156A1 (es) | 2020-07-29 |
| EP3720858B1 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51015A (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci | |
| MA50417A (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
| FR24C1010I2 (fr) | Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux | |
| EP3448389A4 (en) | CHINAZOLINE AND INDOIND DERIVATIVES FOR THE TREATMENT OF MEDICAL DISORDER | |
| EP3471780A4 (en) | TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT | |
| EP3706617A4 (en) | EFFECTIVENESS AND / OR RECOMMENDATION OF THERAPEUTIC PARAMETERS WITH INDIVIDUAL PATIENT DATA AND THERAPEUTIC BRAIN NETWORK MAPS | |
| MA50800A (fr) | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson | |
| EP3861121A4 (en) | RAAV VECTORS FOR THE TREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS | |
| EP4233071A4 (en) | Methods and systems for treating health conditions using prescription digital therapeutics | |
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| EP3405215A4 (en) | METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES | |
| MA44119A (fr) | Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale | |
| EP3639833A4 (en) | AGENTS FOR THE PREVENTION OR TREATMENT OF FAT RELATED DISEASES AND INFLAMMATION | |
| EP3664795A4 (en) | CANNABIS AND DERIVATIVES THEREOF IN THE TREATMENT OF PAIN AND INFLAMMATION ASSOCIATED WITH DENTAL MARSH AND BONE REGENERATION ASSOCIATED WITH JAWBONE DEFECTS | |
| MA53193A (fr) | Vidofludimus à utiliser dans le traitement ou la prévention de maladies virales | |
| EP3735970C0 (en) | CEBRANOPADOL FOR THE TREATMENT OF PAIN IN PATIENTS WITH DECREASED LIVER AND/OR KIDNEY FUNCTION | |
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| EP4054687A4 (en) | Breathing assistance apparatuses and/or components thereof and/or uses thereof | |
| EP3876967A4 (en) | Therapeutic microbiota for the treatment and/or prevention of dysbiosis | |
| EP3937937A4 (en) | TREATMENT OF MITOCHONDRIAL ASSOCIATED DISEASES AND DISORDERS, INCLUDING SYMPTOMS THEREOF; USING PRIDOPIDINE | |
| EP3654961A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN WITH CAPSAICIN | |
| EP3949971A4 (en) | USE OF LUTEOLIN-7-O-GLUCOSIDE OR LUTEOLIN-7-O-GLUCURONIDE IN MANUFACTURE OF MEDICINE FOR EYE INJURIES | |
| EP3840729A4 (en) | TREATMENT OF SPINAL CORD INJURY (SCI) AND BRAIN INJURY USING GSX1 | |
| EP3398614A4 (en) | AGENTS FOR PREVENTION AND / OR TREATMENT OF MORBUS ALZHEIMER | |
| EP3452047A4 (en) | Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith |